Core Insights - Spineway reported a revenue of €12.4 million for the year 2025, reflecting a 4% increase compared to 2024 [4][5] - The gross margin improved to €8.6 million, representing 69.6% of revenue, an increase of 0.6 percentage points year on year [5] - The company experienced a stable operating loss of €2.1 million, consistent with the previous year [5][7] Financial Performance - Revenue for 2025 was €12,430,000, up from €11,950,000 in 2024 [2] - Cost of sales increased to €3,783,000, leading to a gross margin of €8,647,000 [2] - Net operating expenses rose by 5% to €10,780,000, in line with revenue growth [5] - The net loss improved to €2,238,000 from €3,859,000 in 2024 [7] Operational Highlights - The company launched its ESP disc prosthesis production line and continued regulatory investments despite facing delays in approvals and supply chain issues [4] - External financing was limited to €0.4 million in 2025, a significant decrease from €6.8 million in 2024 [8] - Cash position at the end of 2025 was €3.5 million, with net cash after financial debt at €2 million [8] Growth Potential - Consolidated revenue has nearly tripled since 2021, driven by synergies from acquisitions [9] - Continued investment in regulatory affairs, marketing, and R&D is expected to enhance Spineway's growth potential [9]

Core Insights - Spineway achieved a full-year revenue of €12.4 million in 2025, reflecting a 4% increase compared to 2024, despite facing challenges such as postponed approvals in Latin America and delays in Asia [4] - The company experienced a significant acceleration in sales during Q4 2025, with revenue reaching €3.8 million, marking a 34% increase from Q4 2024 [3] Revenue Breakdown - H1 revenue for 2025 was €5.573 million, down 15% from €6.535 million in 2024 [2] - H2 revenue for 2025 was €6.857 million, up 27% from €5.415 million in 2024 [2] - The total revenue for 2025 was €12.430 million, compared to €11.950 million in 2024 [2] Market Performance - The growth in Q4 2025 was attributed to an increase in sales across all markets and the fulfillment of key account orders that were deferred from the first half of the year [3] - The geographical diversification of Spineway, particularly in Asia and Latin America, contributed positively to its performance, allowing the company to enter new countries [4] Future Outlook - Spineway plans to obtain new approvals in 2026 for its premium product ranges in Latin America and Asia, aligning with its commercial development strategy [5] - The company aims to leverage its strong commercial momentum and diversified geographical presence to solidify its position as a major player in spine surgery [5]

Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboration avec Evoluti ...

Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465<td s ...

Press release Ecully, July 30, 2025 – 7 p.m. SPINEWAY H1 2025 results Continued improvement in results and financial positionFull-year 2025 growth target confirmed In thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535Cost of sales(1,702)(2,059)<td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom ...

Press release Ecully, July 3, 2025 – 6:30 p.m. SPINEWAY GMED approval for new production line dedicated to ESP prostheses First production of LP-ESP intervertebral disc prostheses Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received GMED (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral disc prostheses. This approval is a significant strategic miles ...

Company Overview - Spineway designs, manufactures, and markets innovative implants and surgical instruments for treating severe disorders of the spinal column [8] - The company has an international network of over 50 independent distributors, with 70% of its revenue coming from exports [8] General Meeting Highlights - The Combined General Meeting of Spineway shareholders was held on June 4, 2025, with 34,383,058 shares represented, accounting for 100% of voting rights [4] - Resolutions 1, 2, 3, 4, 6, 7, 8, 14, 15, 20, and 21 were approved, while resolutions 5, 9, 10, 11, 12, 13, 16, 17, 18, and 19 were rejected [5] Upcoming Events - The next significant date for the company is July 30, 2025, when half-year sales for 2025 will be reported [6] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), indicating its compliance with certain regulatory frameworks [7]

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]